[go: up one dir, main page]

YU2896A - 9-supstituisani 2-(2-n alkoksifenil)-purin-6-oni, postupak za njihovo pripremanje, i njihova primena u lekovima - Google Patents

9-supstituisani 2-(2-n alkoksifenil)-purin-6-oni, postupak za njihovo pripremanje, i njihova primena u lekovima

Info

Publication number
YU2896A
YU2896A YU2896A YU2896A YU2896A YU 2896 A YU2896 A YU 2896A YU 2896 A YU2896 A YU 2896A YU 2896 A YU2896 A YU 2896A YU 2896 A YU2896 A YU 2896A
Authority
YU
Yugoslavia
Prior art keywords
substituted
ones
preparation
alcoxyphenyl
aplication
Prior art date
Application number
YU2896A
Other languages
English (en)
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of YU2896A publication Critical patent/YU2896A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Pripremanje 9-supstituisanih 2-(2-n-alkoksifenil)-purin-6-ona, formule I, u kojoj E, D i A imaju značenja data u zahtevu 1, vrši se tako što se odgovarajući supstituisani imidazoli ciklizuju pa se tako dobijeni purini derivatizuju. Kao delotvorne supstance u lekovima mogu da se upotrebe 9-supstituisani 2-(2-n-alkoksifenil)-purin-6-oni, naročito u lekovima za lečenje zapaljivih procesa, tromboembolijskih oboljenja, kao i oboljenja srca/krvotoka.
YU2896A 1995-01-19 1996-01-18 9-supstituisani 2-(2-n alkoksifenil)-purin-6-oni, postupak za njihovo pripremanje, i njihova primena u lekovima YU2896A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (1)

Publication Number Publication Date
YU2896A true YU2896A (sh) 1999-03-04

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2896A YU2896A (sh) 1995-01-19 1996-01-18 9-supstituisani 2-(2-n alkoksifenil)-purin-6-oni, postupak za njihovo pripremanje, i njihova primena u lekovima

Country Status (30)

Country Link
US (1) US5866571A (sh)
EP (1) EP0722943A1 (sh)
JP (1) JPH08231546A (sh)
KR (1) KR960029335A (sh)
CN (1) CN1138583A (sh)
AR (1) AR002704A1 (sh)
AU (1) AU4097796A (sh)
BG (1) BG61729B1 (sh)
BR (1) BR9600149A (sh)
CA (1) CA2167349A1 (sh)
CO (1) CO4700524A1 (sh)
CZ (1) CZ16896A3 (sh)
DE (1) DE19501480A1 (sh)
EE (1) EE9600020A (sh)
FI (1) FI960226A7 (sh)
HR (1) HRP960009A2 (sh)
HU (1) HUP9600107A3 (sh)
IL (1) IL116771A (sh)
MA (1) MA23779A1 (sh)
NO (1) NO960221L (sh)
NZ (1) NZ280829A (sh)
PE (1) PE10597A1 (sh)
PL (1) PL312353A1 (sh)
SG (1) SG47379A1 (sh)
SK (1) SK7696A3 (sh)
SV (1) SV1996000004A (sh)
TN (1) TNSN96005A1 (sh)
TR (1) TR199600701A2 (sh)
YU (1) YU2896A (sh)
ZA (1) ZA96399B (sh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
US7501409B2 (en) * 2000-09-06 2009-03-10 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
US7927623B2 (en) * 2001-02-15 2011-04-19 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
ES2294189T3 (es) * 2001-12-13 2008-04-01 Asubio Pharma Co., Ltd. Derivados de pirazolopirimidinona que tienen accion inhibidora de pde7.
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
TNSN96005A1 (en) 2005-03-15
JPH08231546A (ja) 1996-09-10
IL116771A (en) 1999-06-20
HUP9600107A2 (en) 1997-05-28
PE10597A1 (es) 1997-06-13
TR199600701A2 (tr) 1996-08-21
AR002704A1 (es) 1998-04-29
NO960221L (no) 1996-07-22
NO960221D0 (no) 1996-01-18
BG61729B1 (bg) 1998-04-30
IL116771A0 (en) 1996-05-14
PL312353A1 (en) 1996-07-22
FI960226A0 (fi) 1996-01-17
AU4097796A (en) 1996-07-25
ZA96399B (en) 1996-08-14
NZ280829A (en) 1998-04-27
US5866571A (en) 1999-02-02
FI960226A7 (fi) 1996-07-20
HU9600107D0 (en) 1996-03-28
SK7696A3 (en) 1996-08-07
EE9600020A (et) 1996-08-15
HUP9600107A3 (en) 1999-06-28
MA23779A1 (fr) 1996-10-01
SG47379A1 (en) 1998-04-17
CZ16896A3 (en) 1996-08-14
CN1138583A (zh) 1996-12-25
BR9600149A (pt) 1998-01-06
CO4700524A1 (es) 1998-12-29
KR960029335A (ko) 1996-08-17
BG100291A (bg) 1996-07-31
SV1996000004A (es) 1997-02-19
DE19501480A1 (de) 1996-07-25
CA2167349A1 (en) 1996-07-20
EP0722943A1 (de) 1996-07-24
HRP960009A2 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
YU2896A (sh) 9-supstituisani 2-(2-n alkoksifenil)-purin-6-oni, postupak za njihovo pripremanje, i njihova primena u lekovima
YU1496A (sh) 2,8-disupstituisani hinazolinoni, postupak za njihovo dobijanje i njihova primena
YU1396A (sh) 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima
EP0199822A4 (en) Pyrazolecarboxamide derivatives, process for their preparation, and bactericides containing them as effective ingredients.
EP0364797A3 (de) N-Aryl-Stickstoffheterocyclen, mehrere Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide
HUP9602685A2 (hu) Helyettesített kinolin-2-karbonsav-amidok, eljárás előállításukra és alkalmazásuk gyógyszerekként, valamint közbenső termékek
MEP39908A (en) Novel anticholinergic agents that can be used as medicaments and method for the production thereof
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
DE3868076D1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese derivate als aktive bestandteile enthaltende fungizide.
ATE234095T1 (de) Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.
BE865247A (fr) Derives d'acides 5-(2-pyrroyl)-1,2-dihydro-3h-pyrrolo (1,2-a)-pyrrole-1-carboxyliques et leur procede de preparation
FI946073A0 (fi) Vitamiini D-sarjan, 20-asemassa modifioituja johdannaisia, menetelmä tällaisten johdannaisten valmistamiseksi, menetelmässä käytettäviä välituotteita, mainittuja johdannaisia sisältäviä farmaseuttisia valmisteita ja johdannaisten käyttö lääkeaineiden valmistamiseen
NO972128L (no) 2,2-dikloralkankarboksylsyrer, fremgangsmåte for fremstilling av disse, legemiddel inneholdende disse og anvendelse derav for behandling av insulinresistens
HUP9900733A2 (hu) Imidazo[1,2-a]piridin-3-acetamid-származékok alkalmazása a Parkinson-kór és egyéb neuropszihiátriai tünetcsoport kezelésére és e vegyületeket tartalmazó gyógyászati készítmények előállítására
SE8404151D0 (sv) Mellanprodukter for framstellning av azolopyrimidiner
EP0092458A3 (fr) Dérives d'imidazo(1,2-a)pyridine, leur préparation et leur application en thérapeutique
EP0137441A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
ATE335487T1 (de) Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
IT1209758B (it) E-5-(2-alogenovinil-)-2'deossicitidine, loro metodo di preparazione e loro impiego per il trattamentodi malattie da virus
NZ516397A (en) Aminothiazole derivatives and their use as CRF receptor ligands
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
YU31995A (sh) Benzotiofeni glikopiranozida, postupak za njihovo dobijanje i njihova farmaceutska formulacija
FR2456097A1 (fr) Nouveaux derives de la 5 h-furanone-2 et de la 3 h-dihydrofuranone-2, leur procede de preparation et leur application en therapeutique
YU4497A (sh) Novi heteroaril - oksazolidinoni
EP0812844A3 (de) Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung